GlycoMimetics, Inc.

220 articles with GlycoMimetics, Inc.

• GlycoMimetics Reports Top-line Results From Pfizer’s Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease  

  8/3/2019

  GlycoMimetics, Inc. reported that Pfizer Inc. announced that the Phase 3 Rivipansel: Evaluating Safety, Efficacy and Time to Discharge pivotal study did not meet its primary or key secondary efficacy endpoints.

• GlycoMimetics Reports Second Quarter 2019 Financial Results and Recent Operational Highlights

  8/1/2019

  GlycoMimetics, Inc. reported its financial results for the quarter ended June 30, 2019 and highlighted recent business achievements.

• GlycoMimetics to Report Second Quarter 2019 Financial Results on August 1, 2019

  7/25/2019

  The dial-in number for the conference call is (844) 413-7154 (U.S. and Canada) or (216) 562-0466 (international) and entering passcode 8268638.

• GlycoMimetics to Present at Jefferies 2019 Healthcare Conference

  5/29/2019

  GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a corporate update at the Jefferies 2019 Healthcare Conference, on June 5 at 2:00 p.m. ET. in New York, NY.

• GlycoMimetics, Inc. Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease

  5/6/2019

  Since completion of the Phase 2 clinical trial, Pfizer, has been responsible for clinical development of rivipansel, including the RESET clinical trial.

• GlycoMimetics Reports First Quarter 2019 Results and Recent Operational Highlights

  5/2/2019

  GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended March 31, 2019 and highlighted recent company achievements

• GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel

  4/29/2019

  GlycoMimetics, Inc. announced the addition of two senior executives to its executive management team.

• GlycoMimetics to Report First Quarter 2019 Financial Results on May 2, 2019

  4/25/2019

  GlycoMimetics, Inc. announced that it will host a conference call and webcast to report its first-quarter 2019 financial results on Thursday, May 2, 2019, at 8:30 a.m. ET.

• GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML

  4/23/2019

  Evaluating previously untreated newly diagnosed adults with acute myeloid leukemia (AML) who are fit for intensive chemotherapy

• GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359

  4/22/2019

  GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the publication of a paper in Nature Cell Biology that describes how tumor cells engage specific stromal components, most notably E-selectin, for propagation and outgrowth.

• GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359

  4/12/2019

  GlycoMimetics, Inc. (NASDAQ: GLYC) today announced plans to initiate a clinical trial of GMI-1359 in breast cancer patients whose tumors have spread to bone

• GlycoMimetics to Present at Upcoming Investor Conferences

  4/4/2019

  GlycoMimetics, Inc. announced that senior management will present corporate updates at two upcoming investor conferences in April.

• 

  Women's History Month: Top Influential Women in Biopharma

  3/19/2019

  March is National Women’s Month with March 8 specifically designated as International Women’s Day. Although this is not remotely a comprehensive list, BioSpace recognizes these 10 women (in no particular order) as being especially influential in the biopharma industry.

• GlycoMimetics to Present at the Cowen and Company 39th Annual Health Care Conference 2019

  3/7/2019

  GlycoMimetics, Inc. announced that Chief Executive Officer Rachel King will provide a company overview at the Cowen and Company 39th Annual Health Care Conference in Boston, on Tuesday, March 12, 2019, at 9:20 a.m. ET.

• GlycoMimetics Reports Fourth Quarter and Year-End 2018 Results

  3/6/2019

  Initiated first company-sponsored Phase 3 pivotal trial of uproleselan in relapsed/refractory acute myeloid leukemia (AML) at sites in U.S., Europe, Canada and Australia

• GlycoMimetics Announces Transition Plan for Board of Directors

  3/5/2019

  Current Board Member Tim Pearson to become Board Chair effective at the close of the company’s annual meeting on May 17, 2019

• GlycoMimetics to Report Fourth Quarter and Year-End 2018 Financial Results on March 6, 2019

  2/27/2019

  GlycoMimetics, Inc. announced that it will host a conference call and webcast to report its fourth quarter and fiscal year 2018 financial results on Wednesday, March 6, 2018, at 8:30 a.m. ET.

• GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates

  12/4/2018

  GlycoMimetics, Inc. shared at the 60th American Society of Hematology (ASH) Annual Meeting yesterday two posters with preclinical data presentations: on GMI-1687, the company’s highly potent E-selectin antagonist that is bioavailable via subcutaneous administration, and GMI-1757, the company’s dual-function E-selectin/galectin-3 antagonist.

• GlycoMimetics Presents New AML Data with Uproleselan at 60th ASH Annual Meeting

  12/3/2018

  Data in relapsed/refractory and newly diagnosed acute myeloid leukemia (AML) patients underscore clinical opportunities across multiple outcomes measures and subgroups

• 

  Upcoming Highlights from the 60th Annual American Society of Hematology Meeting

  11/30/2018

  The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.